## BACKGROUND. The number of elderly people with small cell lung carcinoma (SCLC) is increasing and currently nearly 25% are older than 70 years. Elderly patients may not tolerate intensive therapy and, therefore, often do not receive such treatment. Additionally, age may be an independent predicto
Treatment of small cell carcinoma of the lung with copp
β Scribed by Nixon, Daniel W.
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 282 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
The COPP regimen (cyclophosphamide, Oncovin, procarbazine, prednisone) was one of the first chemotherapy programs to prolong survival in small cell lung cancer (SCLC) significantly. Results with this regimen in 50 patients with SCLC show an overall median survival of 10 months. Survival was decreased with more extensive disease. Patients given COPP plus irradiation to the primary lesion lived longer than those given COPP alone, but this difference was not statistically significant. Toxicity was relatively mild. The COPP regimen can be considered, especially in advanced SCLC, if coexisting cardiac or renal disease precludes the use of agents toxic to these organs.
π SIMILAR VOLUMES
## Abstract A 64βyearβold man diagnosed to have systemic scleroderma for 1 year developed smallβcell carcinoma of the lung. Six additional cases obtained from the literature describing smallβcell carcinoma occurring in patients with scleroderma are reviewed.